India To Set Lower Margin For MNC Drugs With Local Alternative
This article was originally published in PharmAsia News
Executive Summary
India's regulators plan to limit the ability of multinational drug makers to price their drugs in India if local alternatives are available. The government already is checking on that availability before approving the price of imported brand drugs. If a local alternative is available, the plan is to allow the foreign maker lower margins as a percentage of the landed cost, along with the therapeutic value and the drug's relationship to the quality of life. The government appears united on that aspect of price controls as its chief regulators continue to argue over a new policy. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.